- Home
- BANX vs TLSI Comparison
BANX vs TLSI Comparison
Compare BANX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANX
- TLSI
- Stock Information
- Founded
- BANX 2013
- TLSI 2010
- Country
- BANX United States
- TLSI United States
- Employees
- BANX N/A
- TLSI N/A
- Industry
- BANX Trusts Except Educational Religious and Charitable
- TLSI Medical Specialities
- Sector
- BANX Finance
- TLSI Health Care
- Exchange
- BANX Nasdaq
- TLSI Nasdaq
- Market Cap
- BANX 146.9M
- TLSI 150.0M
- IPO Year
- BANX N/A
- TLSI N/A
- Fundamental
- Price
- BANX $21.39
- TLSI $4.43
- Analyst Decision
- BANX
- TLSI Strong Buy
- Analyst Count
- BANX 0
- TLSI 5
- Target Price
- BANX N/A
- TLSI $10.90
- AVG Volume (30 Days)
- BANX 23.4K
- TLSI 105.5K
- Earning Date
- BANX 06-17-2025
- TLSI 08-12-2025
- Dividend Yield
- BANX 9.66%
- TLSI N/A
- EPS Growth
- BANX N/A
- TLSI N/A
- EPS
- BANX 2.35
- TLSI N/A
- Revenue
- BANX $29,467,794.00
- TLSI $35,990,000.00
- Revenue This Year
- BANX N/A
- TLSI $56.79
- Revenue Next Year
- BANX N/A
- TLSI $54.15
- P/E Ratio
- BANX $8.88
- TLSI N/A
- Revenue Growth
- BANX 2.73
- TLSI 45.50
- 52 Week Low
- BANX $17.99
- TLSI $3.42
- 52 Week High
- BANX $21.67
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- BANX 66.31
- TLSI 41.24
- Support Level
- BANX $21.17
- TLSI $4.80
- Resistance Level
- BANX $21.35
- TLSI $5.10
- Average True Range (ATR)
- BANX 0.26
- TLSI 0.28
- MACD
- BANX 0.06
- TLSI -0.06
- Stochastic Oscillator
- BANX 99.66
- TLSI 2.17
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.